Press Releases

 
Press Releases
  Date Title View
May 19, 2017
BERKELEY, CA -- (Marketwired) -- 05/19/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that updated data from an ongoing Phase 1b/2 study investigating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy developed by Merck (known as MSD outside the United States...
May 8, 2017
BERKELEY, CA -- (Marketwired) -- 05/08/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the first quarter ended March 31, 2017. Cash, cash equivalents and marketable securities were $85.4 million at March 31, 2017 compared to $81.4 million at December 31, 2016. The increase was primarily due to net proceeds...
Apr 3, 2017
BERKELEY, CA -- (Marketwired) -- 04/03/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that the U.S. Food and Drug Administration (FDA) has informed the company that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) will review HEPLISAV-B™ [Hepatitis B Vaccine, Recombinant (Adjuvanted)] at its mee...
Mar 20, 2017
BERKELEY, CA -- (Marketwired) -- 03/20/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will be presenting data on three programs based on stimulation of the immune response using Toll-Like Receptor 9 (TLR9) agonists at the 2017 American Association for Cancer Research Annual Meeting in Washington, D.C. from April 1-5,...
Mar 13, 2017
BERKELEY, CA -- (Marketwired) -- 03/13/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the fourth quarter and year ended December 31, 2016. The net loss for the year ended December 31, 2016 was $112.4 million, or $2.92 per share, compared to $106.8 million, or $3.25 per share, for the year ended Decemb...
Mar 6, 2017
BERKELEY, CA -- (Marketwired) -- 03/06/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced the presentation of findings in patients with metastatic melanoma in the dose escalation phase of an ongoing Phase 1b/2 study investigating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with KEYTRUDA® (pembrolizumab), an anti-P...
Mar 2, 2017
BERKELEY, CA -- (Marketwired) -- 03/02/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that Eddie Gray, Dynavax's chief executive officer, will present at the Cowen and Company 37th Annual Health Care Conference next week in Boston, MA. The presentation will be webcast live and will occur on Monday, March 6, 2017 at 1:20 p.m....
Feb 28, 2017
BERKELEY, CA -- (Marketwired) -- 02/28/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Dynavax's responses to the Complete Response Letter (CRL) issued by the FDA in November 2016 for the Biologics License Application for HEPLISAV-B, the company's vaccin...
Feb 16, 2017
BERKELEY, CA -- (Marketwired) -- 02/16/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that Michael Ostrach, Dynavax's senior vice president and chief financial officer, will present at the 2017 RBC Capital Markets Global Healthcare Conference next week in New York, NY. The presentation will be webcast live and will occur on ...
Jan 9, 2017
BERKELEY, CA -- (Marketwired) -- 01/09/17 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that Eddie Gray, Dynavax's chief executive officer, will present at the J.P. Morgan 35th Annual Healthcare Conference this week in San Francisco, CA. The presentation will be webcast live and will occur on Thursday, January 12, 2016 at 8:30...
1
...
NextLast
= add release to Briefcase